open access

Vol 62, No 4 (2003)
SHORT COMMUNICATIONS
Published online: 2003-09-05
Submitted: 2012-02-06
Get Citation

PCNA and laminin as prognostic factors in primary Fallopian tube carcinoma

Agnieszka Hałoń, Jerzy Rabczyński
Folia Morphol 2003;62(4):475-478.

open access

Vol 62, No 4 (2003)
SHORT COMMUNICATIONS
Published online: 2003-09-05
Submitted: 2012-02-06

Abstract

Primary Fallopian tube carcinoma (PFTC) is one of the rarest malignant tumours of the female genital tract. Staging of the disease according to FIGO scale is the most common prognostic indicator. Others, such as histological type, grading according to Hu classification, depth of tubal wall invasion, the presence of neoplastic cells in peritoneal leakage, invasion of the lymphatic and blood vessels, mitotic activity, DNA ploidy, Ki-67 expression, AgNOR level and p53 and c-erbB-2 immunoreactivity, are not widely accepted.
70 cases of primary Fallopian tube carcinomas were analysed with regard to clinicopathological data, survival and the expression of proliferating cell nuclear antigen (PCNA) and laminin. Histological classification of PTFC revealed 26 cases of the endometriod type, 16 undifferentiated, 15 serous, 8 urothelial, 3 clearcell and 3 of other types. A total of 70 cases revealed positive nuclear staining for PCNA. The index of PCNA (labelling index, LI, proportion of PCNA-positive cells relative to all neoplastic cells) was evaluated. PCNA LI values were classified as high, > 0.45, or low, ≤ 0.45. Intracellular expression of laminin was found in 46 cases and extracellular in 28 cases. There was no significant correlation between the expression and distribution of laminin and survival. The p value was statistically significant only for PCNA LI as an independent prognostic factor.

Abstract

Primary Fallopian tube carcinoma (PFTC) is one of the rarest malignant tumours of the female genital tract. Staging of the disease according to FIGO scale is the most common prognostic indicator. Others, such as histological type, grading according to Hu classification, depth of tubal wall invasion, the presence of neoplastic cells in peritoneal leakage, invasion of the lymphatic and blood vessels, mitotic activity, DNA ploidy, Ki-67 expression, AgNOR level and p53 and c-erbB-2 immunoreactivity, are not widely accepted.
70 cases of primary Fallopian tube carcinomas were analysed with regard to clinicopathological data, survival and the expression of proliferating cell nuclear antigen (PCNA) and laminin. Histological classification of PTFC revealed 26 cases of the endometriod type, 16 undifferentiated, 15 serous, 8 urothelial, 3 clearcell and 3 of other types. A total of 70 cases revealed positive nuclear staining for PCNA. The index of PCNA (labelling index, LI, proportion of PCNA-positive cells relative to all neoplastic cells) was evaluated. PCNA LI values were classified as high, > 0.45, or low, ≤ 0.45. Intracellular expression of laminin was found in 46 cases and extracellular in 28 cases. There was no significant correlation between the expression and distribution of laminin and survival. The p value was statistically significant only for PCNA LI as an independent prognostic factor.
Get Citation

Keywords

primary Fallopian tube cancer; proliferation; invasiveness; prognosis; survival

About this article
Title

PCNA and laminin as prognostic factors in primary Fallopian tube carcinoma

Journal

Folia Morphologica

Issue

Vol 62, No 4 (2003)

Pages

475-478

Published online

2003-09-05

Bibliographic record

Folia Morphol 2003;62(4):475-478.

Keywords

primary Fallopian tube cancer
proliferation
invasiveness
prognosis
survival

Authors

Agnieszka Hałoń
Jerzy Rabczyński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By  "Via Medica sp. z o.o." sp.k., Świętokrzyska 73, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl